A study of Oral CR845 in non-dialysis chronic kidney disease (CKD) associated pruritus population.
Phase of Trial: Phase I
Latest Information Update: 03 Aug 2017
At a glance
- Drugs Difelikefalin (Primary)
- Indications Pertussis
- Focus Adverse reactions
- 03 Aug 2017 According to a Cara Therapeutics media release, the company expects to initiate this trial in the fourth quarter of 2017.
- 18 Jul 2017 New trial record
- 12 Jul 2017 According to a Cara Therapeutics media release, the data from trial (700271091) will help to initiate a clinical trial of an oral CR845 in non-dialysis CKD-associated pruritus patients in 2017.